medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2014, Number 10

<< Back Next >>

Ginecol Obstet Mex 2014; 82 (10)

Diagnosis and treatment of hemophilia A acquired during postpartum

Castillo-Cañadas AM, Serrano-Diana C, López-Del Cerro E, Gómez-García MT, González MG

Language: Spanish
References: 19
Page: 688-696
PDF size: 331.16 Kb.


ABSTRACT

Acquired hemophilia A is a truly exceptional hemorrhagic diathesis, that consists of the emergence of polyclonal autoantibodies (inhibitor) IgG-type (subclasses 1 and 4, in most cases) against the coagulant function of the circulating factor VIII, which acts in the domains C2, A2 and A3 of the molecule, thus interfering their interaction with the factor IXa, the phospholipids and the Von Willebrand factor. Its morbidity and mortality are high, but nevertheless its low incidence (1-1.5 cases per million population per year) is the most frequent autoimmune disorder. This paper reports the clinical case of two patients; the first one, 36 years old, who the tenth day of postpartum required re-entry due to a diagnosis of hematoma of the abdominal wall that was surgically drained twice. The patient of case 2 was 39 years old and at six days of postpartum went to the emergency room due to bleeding, she was underwent to curettage and therapeutic transfusion of 3 UCH. Because of the persistence of bleeding, which was not possible to control with medical treatment and conservative measures, therapeutic hysterectomy was performed, with blood transfusion later. Due to the hemorrhagic complications of this condition and the serious clinical consequences derived from them, it is important to establish an early diagnosis; it is therefore critical to know the existence of this very rare disease to be able to avoid its consequences.


REFERENCES

  1. Collins PW, Hirsch S, Baglin T, Dolan G, Hanley J, et al. Acquired haemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007;109:1870-1877.

  2. Kitchen S, McCraw A, y Marión Echenagucia para el Comité de Ciencias de Laboratorio de la FMH. Diagnosis of Haemophilia and Other Bleeding Disorders. 2a ed. Montreal: WFH, 2010. Disponible en formato impreso en inglés y español. También puede descargarse gratuitamente en www.wf.org.

  3. Huth-Kühne A, Baudo F, Collins P, Ingerslev J, Kessler C, et al. International recommendations on the diagnosis and treatment of patients with acquired haemophilia. Haematologica 2009; 94:566-575.

  4. Hauser I, Schneider B, Lechner K. Post-partum factor VII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Trombosis and Haemostasis 1995;73:1-5.

  5. Freire M, Botelho Teodoro R, Aparecida Nogueira D, Castanheira RitaDP, Ribeiro Filho E, Vieira de Sousa. L. Hemofilia A adquirida associada a artrite reumatoide. Rev Bras Reumatol 2009.

  6. Oldenburg J, Zeitler H, Pavlova A. Genetic markers in acquired hemophilia. Haemophilia 2010;16:41-5.

  7. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors’ Organisation. Br J Haematol 2006;133:591-605.

  8. Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003;121:21-35.

  9. Collins PW. Treatment of acquired hemophilia A. J Thromb Haemost 2007;5:893-900.

  10. Chistolini A, Ghirardini A, Tirindelli MC. Inhibitor to factor VIII in a nonhaemophilic patient: evaluation of the response to DDAVP and the in vitro kinetics of factor VIII. Neuve Revue Francaise Haematologie 1987;29:221-224.

  11. Lak M, Sharifian RA, Karimi K, Mansouritorghabeh H. Acquired hemophilia A: clinical features, surgery and treatment of 34 cases, and experience of using recombinant factor VIIa. Clin Appl Thromb Hemost 2010;16:294-300.

  12. Hay CR, Negrier C, LudlamCA. The treatment of bleeding in acquired hemophiliawith recombinant factor VIIa: a multicenter study. Thromb Haemost 1997;78:1463-7.

  13. Sumner MJ, Geldziler BD, Pedersen M, Seremetis S. Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisal. Haemophilia 2007;13:451- 61.

  14. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-8.

  15. Sallah S. Treatment of acquired hemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004;10:169-73.

  16. Collins P, Baudo F, Heuth-Kuhne A, Ingerslev J. et al. Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes 2010;3:161.

  17. Baudo F, Collins P, Heuth-Kuhne A, Levesque H, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120:39-46.

  18. Collins P, Baudo F, Knoebl P, Levesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Heuth-Kuhne A. Immunosupression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood 2012;120:47-55.

  19. Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002;100:3426-3428.




2020     |     www.medigraphic.com